Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1994 1
1996 2
1999 2
2000 1
2001 2
2006 1
2007 1
2008 3
2010 4
2011 3
2012 7
2013 4
2014 2
2015 2
2016 10
2017 2
2018 2
2019 2
2020 2
2021 3
2022 2
2023 2
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

57 results

Results by year

Filters applied: . Clear all
Page 1
A Phase 1b/2a Trial of a Half-life Extended Respiratory Syncytial Virus Neutralizing Antibody, Clesrovimab, in Healthy Preterm and Full-term Infants.
Madhi SA, Simões EAF, Acevedo A, Novoa Pizarro JM, Shepard JS, Railkar RA, Cao X, Maas BM, Zang X, Krick A, Roadcap B, Vora KA, Aliprantis AO, Lee AW, Sinha A. Madhi SA, et al. Among authors: aliprantis ao. J Infect Dis. 2025 Mar 17;231(3):e478-e487. doi: 10.1093/infdis/jiae581. J Infect Dis. 2025. PMID: 39601265 Free PMC article. Clinical Trial.
Gut microbiota induce IGF-1 and promote bone formation and growth.
Yan J, Herzog JW, Tsang K, Brennan CA, Bower MA, Garrett WS, Sartor BR, Aliprantis AO, Charles JF. Yan J, et al. Among authors: aliprantis ao. Proc Natl Acad Sci U S A. 2016 Nov 22;113(47):E7554-E7563. doi: 10.1073/pnas.1607235113. Epub 2016 Nov 7. Proc Natl Acad Sci U S A. 2016. PMID: 27821775 Free PMC article.
Quantification of clesrovimab, an investigational, half-life extended, anti-respiratory syncytial virus protein F human monoclonal antibody in the nasal epithelial lining fluid of healthy adults.
Phuah JY, Maas BM, Tang A, Zhang Y, Caro L, Railkar RA, Swanson MD, Cao Y, Li H, Roadcap B, Catchpole AP, Aliprantis AO, Vora KA. Phuah JY, et al. Among authors: aliprantis ao. Biomed Pharmacother. 2023 Dec 31;169:115851. doi: 10.1016/j.biopha.2023.115851. Epub 2023 Nov 14. Biomed Pharmacother. 2023. PMID: 37976891 Free article.
Osteoclasts: more than 'bone eaters'.
Charles JF, Aliprantis AO. Charles JF, et al. Among authors: aliprantis ao. Trends Mol Med. 2014 Aug;20(8):449-59. doi: 10.1016/j.molmed.2014.06.001. Epub 2014 Jul 6. Trends Mol Med. 2014. PMID: 25008556 Free PMC article. Review.
A phase I study to evaluate safety, pharmacokinetics, and pharmacodynamics of respiratory syncytial virus neutralizing monoclonal antibody MK-1654 in healthy Japanese adults.
Orito Y, Otani N, Matsumoto Y, Fujimoto K, Oshima N, Maas BM, Caro L, Aliprantis AO, Cox KS, Tokumaru O, Kodama M, Kudo H, Imai H, Uemura N. Orito Y, et al. Among authors: aliprantis ao. Clin Transl Sci. 2022 Jul;15(7):1753-1763. doi: 10.1111/cts.13290. Epub 2022 May 17. Clin Transl Sci. 2022. PMID: 35506164 Free PMC article. Clinical Trial.
Vericiguat: A Randomized, Phase Ib, Placebo-Controlled, Double-Blind, QTc Interval Study in Patients with Chronic Coronary Syndromes.
Böttcher M, Düngen HD, Corcea V, Donath F, Fuhr R, Gal P, Mikus G, Trenk D, Coenen M, Pires PV, Maschke C, Aliprantis AO, Besche N, Becker C. Böttcher M, et al. Among authors: aliprantis ao. Am J Cardiovasc Drugs. 2023 Mar;23(2):145-155. doi: 10.1007/s40256-022-00557-2. Epub 2023 Jan 12. Am J Cardiovasc Drugs. 2023. PMID: 36633816 Free PMC article. Clinical Trial.
U-BIOPRED clinical adult asthma clusters linked to a subset of sputum omics.
Lefaudeux D, De Meulder B, Loza MJ, Peffer N, Rowe A, Baribaud F, Bansal AT, Lutter R, Sousa AR, Corfield J, Pandis I, Bakke PS, Caruso M, Chanez P, Dahlén SE, Fleming LJ, Fowler SJ, Horvath I, Krug N, Montuschi P, Sanak M, Sandstrom T, Shaw DE, Singer F, Sterk PJ, Roberts G, Adcock IM, Djukanovic R, Auffray C, Chung KF; U-BIOPRED Study Group. Lefaudeux D, et al. J Allergy Clin Immunol. 2017 Jun;139(6):1797-1807. doi: 10.1016/j.jaci.2016.08.048. Epub 2016 Oct 20. J Allergy Clin Immunol. 2017. PMID: 27773852 Free article.
IL-17-high asthma with features of a psoriasis immunophenotype.
Östling J, van Geest M, Schofield JPR, Jevnikar Z, Wilson S, Ward J, Lutter R, Shaw DE, Bakke PS, Caruso M, Dahlen SE, Fowler SJ, Horváth I, Krug N, Montuschi P, Sanak M, Sandström T, Sun K, Pandis I, Auffray C, Sousa AR, Guo Y, Adcock IM, Howarth P, Chung KF, Bigler J, Sterk PJ, Skipp PJ, Djukanović R, Vaarala O; U-BIOPRED Study Group. Östling J, et al. J Allergy Clin Immunol. 2019 Nov;144(5):1198-1213. doi: 10.1016/j.jaci.2019.03.027. Epub 2019 Apr 15. J Allergy Clin Immunol. 2019. PMID: 30998987 Free article. Clinical Trial.
A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults.
Aliprantis AO, Shaw CA, Griffin P, Farinola N, Railkar RA, Cao X, Liu W, Sachs JR, Swenson CJ, Lee H, Cox KS, Spellman DS, Winstead CJ, Smolenov I, Lai E, Zaks T, Espeseth AS, Panther L. Aliprantis AO, et al. Hum Vaccin Immunother. 2021 May 4;17(5):1248-1261. doi: 10.1080/21645515.2020.1829899. Epub 2020 Oct 29. Hum Vaccin Immunother. 2021. PMID: 33121346 Free PMC article. Clinical Trial.
57 results